Company Sanguine Corporation

Equities

SGUI

US8010062060

Biotechnology & Medical Research

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Sanguine Corporation -.--% -.--%

Business Summary

New Alliance Biosciences, Inc., formerly Sanguine Corporation, through its subsidiary, SGN LifeSciences, is engaged in discovering, developing and commercializing novel biotechnologies. The company is focused on the development and commercialization of perfluorocarbon based therapeutic oxygen carriers. The Company's core product, PHER-02, is a perfluorocarbon emulsion. PHER-O2 is made up of perfluoro-decalin, which is a type of perfluorocarbon that is harmless to humans and the atmosphere and was used in Fluosol, purified water and a surfactant to hold the emulsion together. PHER-O2 is ideal for medical indications, such as transportation of pancreas islets for treatment of diabetes, ophthalmic retinal surgery, traumatic brain injury, nuclear magnetic resonance imaging, and treatment of heart attacks.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 7,246,822 3,745,165 ( 51.68 %) 0 51.68 %
Stock B 0 75,000 0 0

Company contact information

New Alliance Biosciences, Inc.

110 Founders Mill Court

30075, Roswell

+

address Sanguine Corporation(SGUI)
  1. Stock Market
  2. Equities
  3. SGUI Stock
  4. Company Sanguine Corporation